A woman in her forties sits in my office six weeks out from her last drink. She has been told by two programs that she needs more willpower and a stronger commitment to the steps. Nobody has mentioned that three FDA-approved medications exist for her condition, and that she has never been offered any of them. In my experience this happens far more often than it should, and a new review in CNS Drugs helps explain why the conversation matters.
What the CNS Drugs Review Found
Itai Danovitch and colleagues ran an umbrella review, which means they gathered existing systematic reviews and examined them together instead of starting from scratch. The paper, published online September 23, 2026, worked through 16 systematic reviews that covered 371 randomized trials with 131,965 participants, along with 62 observational studies. It examined 41 approved medications built from 25 distinct molecules for substance use disorders.
The tobacco evidence is the largest, with 223 trials and 104,524 participants. Varenicline more than doubled smoking cessation compared with placebo (risk ratio 2.32, 95% confidence interval 2.15 to 2.51). Bupropion SR raised cessation by 64% (risk ratio 1.64) and nicotine replacement therapy by 55% (risk ratio 1.55).
For opioid use disorder, methadone had significantly higher retention in treatment at six months than buprenorphine (risk ratio 0.76 for buprenorphine). At the 300/300 mg dose of extended-release buprenorphine, 41.3% of patients were abstinent compared with 5.0% on placebo. Across 41 observational studies of 74,114 people, survival after naloxone ranged from 92% to 98%.
What the Alcohol Numbers Say
Alcohol use disorder had 86 trials and 18,643 participants. Acamprosate reduced the risk of returning to any drinking by 12%. Oral naltrexone at 50 mg reduced the risk of any drinking by 7% (risk ratio 0.93) and the risk of heavy drinking by 19% (risk ratio 0.81). Disulfiram did not reduce the return to any drinking by more than chance would explain.
I want patients to read those figures carefully. Twelve percent and nineteen percent are modest effects, and they are the reason I do not describe any single pill as a solution. They are also real effects that stack with counseling, sleep repair, nutrition, and treatment of co-occurring depression or trauma. A physician who prescribes naltrexone and then ends the visit has not treated the whole brain. A program that refuses to discuss naltrexone at all has left a measurable benefit on the table.
The Gap Nobody Should Accept
The review found no approved medication for caffeine, cannabis, hallucinogen, inhalant, or stimulant use disorders. For methamphetamine, the pipeline section describes ADAPT-2, a phase 3 trial of injectable naltrexone plus oral bupropion. It reported an overall weighted treatment effect of 11.1%, which works out to a number needed to treat of 9 for one additional responder.
Think about who this leaves behind. A construction foreman in his thirties using methamphetamine, or a college student whose daily cannabis use has taken over her semester, walks into the same clinic as the person with opioid or tobacco dependence and finds an empty shelf. Our recent coverage of the mitochondrial calcium switch that opioids and meth flip describes the kind of biology that new drug development could target, and the review makes clear how far the field still has to travel.
The review also describes its own limits. Each of the four pipeline agents it covers is represented by a single trial instead of a systematic review, so those results rest on far less evidence than the approved medications do.
What This Means for You
If you or someone you love is in treatment for alcohol, opioids, or tobacco, ask the prescriber directly which approved medications fit your situation and why or why not. If you are told a medication is unnecessary because you are motivated, that is not a medical reason. If the substance is methamphetamine or cannabis, ask what behavioral and supportive care the program provides, and ask about clinical trials, because that is where the next options will come from.
At Rescue From Rehab we begin with precision diagnostics, including cognitive testing and brain imaging where indicated, and then build a plan that pairs the right medication, when one exists, with the nutrition, sleep, and neurological support the individual brain needs. Some patients also ask about brain-supportive supplements, and we discuss those honestly, including how limited the evidence remains, through resources like Action Potential Supplements.
Addiction is a treatable brain condition, and the 371 trials behind this review are the evidence that treatment works when it is matched to the person. Every patient deserves to hear what the options are, and to be told plainly when the options run out.
This article was drafted with the assistance of AI writing tools, then reviewed, edited, and approved by Dr. Drew W. Edwards, Ed.D., who holds full editorial responsibility for its content.
Sources
Danovitch I, Truman K, Brown H, et al. Approved Medications for Substance Use Disorders: An Umbrella Review of Systematic Reviews and Completed Phase 3 Randomized Controlled Trials. CNS Drugs. Published online September 23, 2026. doi:10.1007/s40263-026-01334-4.
Hero image: AI-generated illustration. Illustration created with AI image tools.